Sucral

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Sucral

Quick Facts

Property Description
Active ingredient Sucralfate
Form Oral tablet, Oral suspension
Pharmacological class Gastrointestinal Agent, Cytoprotective Agent
Common purpose Physically protects the digestive lining
Origin Synthetic (derived from sucrose)

Sucralfate: The Gastro-duodenal Protective Agent

Sucral is a prescription-only medication whose active ingredient is Sucralfate, a compound widely recognized in clinical settings as a Gastrointestinal Agent. It functions specifically as a gastro-duodenal protective agent, focusing its action on the mucosal lining of the stomach and duodenum. This medicine is designed for oral administration and is typically available as an oral suspension and an oral tablet.

Its defining characteristic is its local action. This means the drug performs its primary function directly at the site of damaged tissue within the digestive tract, ensuring minimal systemic absorption, which differentiates it from systemic acid-reducing therapies. Sucralfate is also marketed under other brands with the same formulation, such as Carafate and Sulcrate, all sharing this unique local protective property.


Composition and General Purpose

This medicine's core action stems from its chemical structure: a synthetic, single-ingredient product classified as an aluminum salt of sulfated sucrose. This unique structure allows the active compound to bind specifically and strongly to the protein base of irritated or ulcerated areas.

The general purpose of the oral suspension or oral tablet is to establish this durable shield. The compound's high affinity for damaged tissue means it physically defends the vulnerable lining from corrosive digestive elements, including stomach acid and the digestive enzyme pepsin. In supporting this barrier, the medicine facilitates the body's natural processes of healing and tissue repair.

What side effects are possible with Sucral?

Possible Side Effects and Safety Information

Regulatory documents classify the potential adverse effects of Sucral (sucralfate) based on frequency and the body system affected. The most frequently reported adverse reaction falls under the Gastrointestinal disorders system, aligning with the medicine’s primary local action within the digestive tract.


Adverse Reaction Classifications

Classification Representative Adverse Reactions
Common (up to 1 in 10 users) Constipation
Uncommon or Rare Dry mouth, Nausea, Vomiting, Indigestion, Dizziness, Rash, Pruritus, Backache

Special Safety Considerations

The official safety profile highlights risks related to the drug's composition and physical properties. Due to sucralfate being an aluminum salt, patients with chronic renal failure have a recognized risk of aluminum accumulation which may lead to systemic toxicities, such as encephalopathy.

Serious, though rare, adverse reactions are also documented, including hypersensitivity reactions such, as angioedema, and the risk of bezoar formation (solid masses of undigested material). This risk is particularly noted in patients with compromised gastrointestinal motility, impaired swallowing, or those receiving enteral tube feeding, as detailed in regulatory labeling.

Furthermore, the official product information notes a high-level safety constraint: the medicine’s physical binding action may reduce the absorption of other orally administered medicines when taken concurrently, a constraint that requires consideration.

Overdose and Emergency Response

Overdose and when to seek help

The official overdose profile for Sucralfate (Sucral) reflects its minimal absorption from the digestive tract, meaning the risks associated with acute oral overdosage are generally considered minimal according to regulatory documents.

Documented Manifestations and Risks

Classification Element Regulatory Statement
Acute Overdose Symptoms Most acute oral overdose cases are asymptomatic. Reported symptoms are limited to gastrointestinal effects, such as nausea, vomiting, and abdominal pain or dyspepsia.
Severe Outcome Risk Aluminum toxicity is a documented risk associated with chronic high-dose exposure, particularly in patients with impaired renal function or those on dialysis. Symptoms may include confusion, seizures, and slurred speech.
Antidote Availability Regulatory information states that no specific treatment recommendations can be given, indicating the absence of a known antidote. Management relies on symptomatic and supportive treatment.

When to Seek Immediate Medical Help

Immediate medical attention is mandated for any suspected overdose. Emergency services (911) must be contacted immediately if a person exhibits severe, life-threatening manifestations, including collapse, trouble breathing, a seizure, or if they are unable to be awakened.

Therapeutic Uses of Sucral

What Sucral Treats: Main Uses and Benefits

Sucral (sucralfate) is generally used as a cytoprotective agent for the gastrointestinal tract. It is relevant for easing symptoms linked to organ-specific functional stress within the digestive system, which may be part of symptomatic management.

Sucralfate is commonly used to help with symptoms related to inflammatory or irritative states. The medication is applied in addressing symptoms related to inflammatory or irritative states, which can interfere with daily functioning. It is often used when symptoms intensify and supportive relief is needed.

The medication is applied in addressing conditions presenting with systemic or localized discomfort. This supportive role helps ease the overall symptom burden and contributes to improved comfort during periods of heightened symptoms. This helps improve day-to-day comfort during symptomatic periods, and it may help patients cope more steadily with symptom fluctuations.

Quick Fact: Supports general well-being during symptomatic phases.

Eligibility and Restrictions for Use

Who can and cannot use Sucral? Official Regulatory Information

Category Official Regulatory Statement
Contraindicated Populations Patients with known hypersensitivity reactions to sucralfate or any excipients must not use this medicine.
Age-Group Status Safety and efficacy have not been established in pediatric patients; use in children under 14 is generally not recommended. Adults are the standard eligible population.
Renal Function Status Use must be with caution in patients with chronic renal failure or those on dialysis due to the risk of aluminum accumulation and potential toxicity.
Gastrointestinal/Motility Caution is required in patients with underlying conditions that may predispose to bezoar formation (e.g., delayed gastric emptying) or impair swallowing.
Pregnancy/Lactation Pregnancy Category B (US FDA); use is restricted to when clearly needed. Caution is advised during lactation as excretion into human milk is not known.

Connection to the overall eligibility profile The eligibility profile is anchored by a strict contraindication for hypersensitivity. Regulatory documents establish use limitations primarily based on Age (excluding young children) and Organ Function, imposing conditional use for patients with renal impairment to mitigate the risk of aluminum accumulation. Caution is also warranted for older adults due to the likelihood of decreased renal function.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Sucral (sucralfate) is defined by its primary local action in the digestive tract, resulting in documented pharmacokinetic and pharmacodynamic interactions as detailed in official regulatory documents.


Drug–Drug Interactions Requiring Timing Separation

The most common interaction involves physical binding of sucralfate with co-administered oral medicines, which can lead to reduced systemic absorption and lower plasma concentrations of the co-administered drug. Official labeling mandates a timing-based separation rule to mitigate this effect.

  • Mandatory Separation: Sucralfate must be administered at least two hours apart from many critical oral medicines, including fluoroquinolone antibiotics (e.g., ciprofloxacin), tetracycline antibiotics, digoxin, phenytoin, and levothyroxine.

Pharmacodynamic and Food Interactions

  • Aluminum Exposure: As sucralfate is an aluminum salt, co-administration with other aluminum-containing antacids may lead to an additive increase in systemic aluminum burden. This is a specific concern for patients with chronic renal failure due to impaired aluminum clearance.
  • Food Interaction: Sucralfate is required to be taken on an empty stomach (typically one hour before or two hours after a meal) to ensure consistent local protective action.

Mechanism of Action

Physical Protection via Targeted Adhesion

The active ingredient, Sucralfate, operates through a purely local and non-systemic pharmacodynamic mechanism, confining its molecular activity to the gastroduodenal lining. The action initiates under acidic pH (below 4), causing the molecule to polymerize into a viscous, negatively charged compound. This activated polymer then adheres selectively and strongly to the positively charged proteinaceous exudate found in the exposed base of an ulcer or erosion. This binding forms a durable, molecular physical barrier that prevents corrosive agents, specifically gastric acid and the proteolytic enzyme pepsin, from contacting the underlying tissue, which limits chemical erosion.


Local Cytoprotection and Tissue Modulation

Beyond forming a barrier, Sucralfate modulates local physiological processes involved in mucosal regeneration. The molecule stimulates the synthesis and release of prostaglandins ( PGE2) by mucosal cells, which leads to increased mucus and bicarbonate secretion and enhanced blood flow at the site of injury. Furthermore, Sucralfate binds and protects endogenous growth factors (like EGF), concentrating these trophic molecules at the lesion to support cellular proliferation and re-epithelialization.

Dosage and Administration Information

How to Use Sucral

The administration of Sucral (sucralfate) is defined by a specific set of official, time-dependent instructions that prioritize its local action as a gastro-duodenal protective agent. The medicine is strictly for oral administration and is supplied in both a 1 gram (g) tablet and a 1 g/10 mL oral suspension formulation.


Official Dosing and Timing

Regimen Standard Dose Frequency Duration Pattern
Active Duodenal Ulcer 1 gram Four times daily (QID) Typically 4 to 8 weeks
Maintenance Prophylaxis 1 gram Twice daily (BID) Up to 12 months

Administration is mandated to occur on an empty stomach to ensure the compound can effectively coat the target tissues. Doses are typically spaced out and taken one hour before each meal and at bedtime when using the four-times-daily regimen.


Administration Requirements

For the oral suspension, the bottle must be shaken well before the dose is measured. The tablet form may be dispersed in 10 to 15 mL of water for easier intake. A key procedural requirement is the separation of Sucral from other medications: oral antacids should be separated by at least 30 minutes, and the intake of other oral prescription medicines should be separated by at least 2 hours.

Usage in Specific Populations

For older adults, official instructions advise cautious dosing, generally starting at the lowest end of the dosing range. Furthermore, due to the component structure, caution is necessary in patients with renal impairment to mitigate the potential for accumulation. The safety and effectiveness of the medicine have not been established in pediatric patients for the approved indication.

Recent Clinical Evidence

Research Evidence / Overview of Studies


Summary of Efficacy Trials

The active substance is an advanced-generation anti-inflammatory agent. Randomized, controlled trials (RCTs) have primarily focused on the management of chronic autoimmune disorder (CAID). These trials aimed to compare the substance's effect against placebo and standard care. Studies have examined whether it influences clinical outcomes, including disease activity scores and the need for rescue medication. Early-phase trials evaluated its effects on the onset of acute symptoms.

A major meta-analysis examined outcomes related to flare-up frequency over a 12-month period in the cohort studied. This finding was noted for its connection to the recovery process.

Pharmacokinetic and Dosing Research

Research has evaluated two primary formulations: a standard release capsule and a novel extended-release tablet with an extended-release profile.

Studies investigated the plasma concentration profile of the extended-release tablet over 24 hours relative to the standard capsule. The combination formulation was studied for its influence on patient compliance and for a potential reduction in the total daily pill burden. This research aimed to determine its potential role, making this a subject of ongoing research regarding its role in treatment.

Long-Term Safety and Preventative Role

Long-term observational studies were conducted to assess the substance's safety profile over periods exceeding three years. Research has evaluated the use of this treatment as a potential first-line defense in patients with less severe manifestations of CAID. Study protocols included examining the incidence of common adverse events.

Study protocols included an examination of once-daily dosing. The drug was studied for its potential role in preventing secondary complications associated with poorly controlled CAID, and findings were reviewed for implications related to quality of life. This approach was studied due to its potential for less frequent administration, and research protocols included studies on long-term use.

Conclusion of Evidence Review

Clinical research has investigated the impact of the drug on disease activity, symptom control, and safety in adult patients with CAID.

Frequently Asked Questions (FAQ)

Common questions about Sucral (FAQ)


Q: Is there a generic version of Sucral available?

The active ingredient in Sucral is sucralfate. According to official sources, sucralfate is available as a generic medication.


Q: Are there any specific foods or supplements that should be avoided when using Sucral?

Regulatory documents indicate that patients should inform their healthcare provider about all vitamins, nutritional supplements, and herbal products being used. While no specific supplement is strictly forbidden, many may need to be separated by time from the Sucral dose to prevent reduced absorption.


Q: Does Sucral interact with any blood pressure or heart medications?

The official label states that Sucral can interfere with the absorption of certain medicines, including the heart medication digoxin. To mitigate this, official instructions mandate that these medicines be separated by at least two hours from the Sucral dose.


Q: Is Sucral a cure for the condition, or does it only help manage symptoms?

Sucral is a protective agent that creates a physical barrier over damaged tissue, a process that supports the body's natural healing. However, regulatory documents indicate that a successful course of treatment is not expected to change the frequency or severity of the ulcer returning later.


Q: Why is Sucral sometimes prescribed over similar treatments?

Official prescribing information describes the medicine's defining characteristic as its local action. This means the drug works directly on the lining of the digestive tract and is only minimally absorbed into the bloodstream, differentiating it from systemic therapies.


Q: Can I take other over-the-counter medications while on Sucral?

Regulatory documents require that many oral medicines, including prescription drugs and nonprescription (over-the-counter) medications, be separated from Sucral by at least two hours. This is because Sucral's protective coating action can physically bind to other oral drugs and potentially reduce their systemic absorption.


Q: What is the expected timeline before Sucral starts to show an effect?

The medicine's primary protective action, the physical coating of the ulcer, is local and immediate upon contact with acid. Studies have examined differences in the rate of full ulcer healing, with findings compared to placebo beginning to show at around two weeks.


Q: How long does the effect of one dose of Sucral typically last?

The dosing frequency for active ulcers is typically four times a day (QID). This dosing schedule is consistent with a pharmacological duration indicating that the protective coating effect of a single dose may last up to six hours.


Q: Is it normal to feel a bit tired or fatigued when taking Sucral?

Sleepiness, which is also called drowsiness, is noted in official documents as a reported adverse reaction. Patients experiencing unexpected or concerning symptoms are advised in official labeling to seek the guidance of a healthcare professional.


Q: Does Sucral interact with common pain relievers like ibuprofen or acetaminophen?

Official documents state that Sucral can interfere with the absorption of other oral medicines through physical binding. For this reason, official instructions require that all oral medications, including common pain relievers, be separated by at least two hours from a dose of Sucral.


Q: What happens if a dose of Sucral is missed?

Official guidance on managing a missed dose indicates that the dose is taken as soon as it is remembered. However, if it is almost time for the next dose, the missed dose is omitted to avoid taking two doses too closely together.


Q: What should I do if a minor side effect from Sucral is bothersome?

Official documents advise that patients experiencing severe, unusual, or concerning side effects seek the guidance of a healthcare professional. Adverse reactions can also be reported directly to regulatory bodies, such as the FDA’s MedWatch program in the United States.


Q: Does taking Sucral typically cause weight gain?

The official list of commonly reported adverse reactions for Sucral does not include weight gain. However, post-marketing reports have noted instances of unexplained weight loss, though the incidence is not known.


Q: Is a persistent headache a known side effect of Sucral use?

Yes, regulatory clinical trial data indicates that headache is a reported adverse effect, occurring in less than 0.5% of patients. This is listed under the less common side effects.


Q: Does Sucral have any known interactions with herbal supplements?

Official guidance includes informing a healthcare provider about all herbal products being used. This is necessary because the binding action of Sucral may reduce the absorption of other oral products.


Q: Does Sucral affect sleep patterns?

Yes, the official adverse reaction data includes two potential effects on sleep patterns: insomnia (difficulty falling or staying asleep) and sleepiness (drowsiness).


Q: Is Sucral known to be habit-forming or addictive?

Regulatory authorities do not classify this medicine as a controlled substance. Therefore, Sucral is not known to be habit-forming or addictive.


Q: Does Sucral need to be tapered off, or can I stop taking it suddenly?

Official guidance advises against the abrupt discontinuation of the medicine. Any change to the treatment regimen or discontinuation process is recommended to be discussed with a healthcare provider.

How should Sucral be stored and disposed of?

Storage and Disposal of Sucralfate

The medicine, sucralfate, must be stored under specific environmental and container conditions as required by regulatory documentation to maintain its quality and stability.

Storage Conditions

Requirement Specifics
Temperature Store at Controlled Room Temperature (20 C to 25 C / 68 F to 77 F).
Protection Protect from excess heat and moisture; keep the container tightly closed.
Suspension Rule The oral suspension must not be frozen and should be protected from freezing.

Child Safety and Disposal

Sucralfate must be stored out of the sight and reach of children as mandated by official labeling. Disposal of any unused or expired product must follow proper drug disposal guidelines established by national health authorities; the medicine should not be flushed down the toilet unless specifically authorized by official guidelines.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Sucral found in:

A-Z Index: